Targeting ERBB2 mutations in solid tumors: biological and clinical implications

Preclinical data have shown that ERBB2 activating mutations are responsive to HER2 tyrosine kinase inhibitors. The aim of this study is to characterize the landscape of ERBB2 mutations in solid tumors and the potential efficacy of ERBB2 targeting. We analyzed the next-generation sequencing results f...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Hematol Oncol
Main Authors: Cousin, Sophie, Khalifa, Emmanuel, Crombe, Amandine, Laizet, Yech’an, Lucchesi, Carlo, Toulmonde, Maud, Le Moulec, Sylvestre, Auzanneau, Céline, Soubeyran, Isabelle, Italiano, Antoine
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2018
Fag:
Letter to the Editor
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6019715/
https://ncbi.nlm.nih.gov/pubmed/29941010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0630-4
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker